Form 4: Acadia Pharmaceuticals CEO Stephen Davis Reports Stock Transactions

CEO Stephen Davis of Acadia Pharmaceuticals reports acquisition and disposal of company stock related to vesting of performance stock units and tax obligations.

Summary

• On March 25, 2024, Stephen Davis, CEO of Acadia Pharmaceuticals, acquired 34,666 shares of common stock upon vesting of performance stock units.
• These units were granted on April 5, 2022, and vested at 50% of the target amount.
• On March 27, 2024, Davis sold 17,714 shares of common stock at a price of $17.90 per share.
• The sale was mandatory to cover withholding taxes and tax-related items associated with the vesting of the performance stock units.
• Davis also acquired a stock option to buy 286,451 shares at an exercise price of $17.84 on March 25, 2024.
• 25% of the shares subject to the stock option will vest on March 25, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter.
• Following these transactions, Davis directly owns 118,842 shares of Acadia Pharmaceuticals common stock and has options to purchase 286,451 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to compensation and tax obligations. There's no indication of unusual activity or significant concern.

Positives

• The vesting of performance stock units suggests that certain performance targets were met, which could be viewed positively.

Negatives

• The sale of shares to cover tax obligations, while mandatory, could be interpreted negatively by some investors as a reduction in the CEO's stake.

Risks

• The vesting schedule of the stock options could create future selling pressure if Davis chooses to exercise and sell the shares.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the stock options implies continued service by the CEO.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in company stock. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and vesting schedules are common compensation practices in the pharmaceutical industry, used to align management's interests with those of shareholders.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedule of Acadia's stock options, with 25% vesting after one year and the remainder over the following three years, is fairly standard.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for future dilution from stock option exercises.

Key Dates